Cellnovo Admitted to the SRD Long-Seulement Long-Only Deferred Settlement Service

Regulatory News:

Cellnovo Group (Paris:CLNV) ("Cellnovo” CLNV: EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, today announces that its shares will be admitted to the Euronext Paris SRD (Service de Règlement Différé, i.e. Deferred Settlement Service) from 29 December 2015, on the "Long-seulement” (Long-only) segment.

"SRD Long seulement” allows investors with a French securities account to purchase Cellnovo shares using the leveraged effect of deferred settlement. For the buyer, risks are thus limited to the initial size of the investment. Contrary to the standard Deferred Settlement Service, shares listed on the "Long-seulement” segment are only eligible for purchase, and are not tradable on the centralized borrowing and lending market.

Sophie Baratte, CEO of Cellnovo, commented: "We are pleased to have been admitted to the SRD Long seulement which will mean greater visibility of Cellnovo’s shares and access to a broader base of investors.”

About Cellnovo

An independent medical technology company specialising in diabetes, Cellnovo has developed and markets the first mobile, connected all-in-one diabetes management system that helps make life easier for patients. Compact, tubeless, intuitive and entirely connected, Cellnovo’s insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient’s condition to be continually monitored by family members and healthcare professionals in real-time.

For further information please visit www.cellnovo.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20151210005770/en/